compounded tirzepatide ijamsville 12 Week Program – Elevate Health and Wellness tirzepatide injection ijamsville Eli Lilly

human clinical data is limited

Jama 332 , 910 (2024)

Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach

Peptides are significantly effective, but they should be used carefully under the guidance of experienced healthcare providers